Download

Free Med Pocket Cards

First Interchangeable Biosimilar Insulin Approved

Semglee (insulin glargine-yfgn) is a biosimilar basal insulin with the same chemical composition as insulin glargine. However, since it is a biosimilar, it is a less costly version of this widely popular basal insulin. Up until now, pharmacists could not make “pharmacy-level substitution”—much like how generic drugs are substituted for brand name drugs, without provider approval.

With this new FDA approval, an interchangeable biosimilar product may be substituted for the reference product without the intervention of the prescriber. Biosimilars marketed in the U.S. typically have launched with initial list prices 15% to 35% lower than comparative list prices of the reference products.

Bottom line, the pharmacist can now interchange or substituted semglee for its reference product Lantus (insulin glargine) without prescriber approval.

“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D.

This also has implications for future, lower cost biosimilars says Dr. Woodcock. “Today’s approval of the first interchangeable biosimilar product furthers FDA’s longstanding commitment to support a competitive marketplace for biological products and ultimately empowers patients by helping to increase access to safe, effective and high-quality medications at potentially lower cost.”

Semglee (insulin glargine-yfgn), offered in 10 mL vials and 3 mL prefilled pens, is administered subcutaneously once daily.

Access to affordable insulin is critical and the approval of this first biosimilar heralds good news for future biosimilar interchangeability.

Sign up for Diabetes Blog Bytes!

We post weekly Blog Bytes that are informative and FREE! Every week we post one exam practice Question of the Week and Rationale of the Week. Sign up below!

Form Heading

Newly Expanded Accreditation!​

For more information on accreditation, visit each individual course page in our Online Store and click the “Accreditation” tab

Our course CE credits are through the following accrediting bodies:

  • AMA PRA Category 1 Credits™,
  • ACPE,
  • ANCC, and
  • CDR

Course credits will continue to count toward the CDCES and BC-ADM certification requirements, and many of our offerings (all of Standards of Care Intensive courses, plus our Virtual and Live DiabetesEd Training Conferences) fulfill the ADA Standards of Care component required for certification renewal.

The use of DES products does not guarantee the successful passage of the certification exam. CBDCE and ADCES do not endorse any preparatory or review materials for the CDCES or BC-ADM exams, except for those published by CBDCE & ADCES.

Recent Blog Bytes